Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows

Reuters

2025/11/06

<a href="https://laohu8.com/S/ACRS">Aclaris Therapeutics</a> Q3 revenue beats estimates, net loss narrows

Overview

Aclaris Q3 revenue beats analyst expectations despite a year-over-year decline
Net loss for Q3 smaller than expected, reflecting better financial performance
Company reports positive Phase 2a trial results for ATI-2138 in atopic dermatitis

Outlook

Aclaris plans Phase 2 trial of ATI-2138 in H1 2026 for new indications
Company expects Phase 1b trials of ATI-052 in asthma and AD in H1 2026
Aclaris expects cash runway to fund operations into H2 2028

Result Drivers

NET LOSS - Net loss was $14.6 million for the third quarter of 2025 compared to $7.6 million for the third quarter of 2024.

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Beat	$3.30 mln	$1.59 mln (6 Analysts)
Q3 Net Income	Beat	-$14.61 mln	-$15.80 mln (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00, about 67.7% above its November 5 closing price of $2.26

Press Release: ID:nGNX25vlxp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581218062"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581218062\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581218062?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581218062","market":"us","top_or_hot":-1,"title":"Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> Q3 revenue beats estimates, net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Aclaris Q3 revenue beats analyst expectations despite a year-over-year decline</p></li><li><p>Net loss for Q3 smaller than expected, reflecting better financial performance</p></li><li><p>Company reports positive Phase 2a trial results for ATI-2138 in atopic dermatitis</p></li></ul><p><span>Outlook</span></p><ul><li><p>Aclaris plans Phase 2 trial of ATI-2138 in H1 2026 for new indications</p></li><li><p>Company expects Phase 1b trials of ATI-052 in asthma and AD in H1 2026</p></li><li><p>Aclaris expects cash runway to fund operations into H2 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NET LOSS - Net loss was $14.6 million for the third quarter of 2025 compared to $7.6 million for the third quarter of 2024. </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$3.30 mln</p></td><td><p>$1.59 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$14.61 mln</p></td><td><p>-$15.80 mln (6 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aclaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $7.00, about 67.7% above its November 5 closing price of $2.26</p></li></ul><p>Press Release: <span>ID:nGNX25vlxp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclaris Therapeutics Q3 revenue beats estimates, net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> Q3 revenue beats estimates, net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Aclaris Q3 revenue beats analyst expectations despite a year-over-year decline</p></li><li><p>Net loss for Q3 smaller than expected, reflecting better financial performance</p></li><li><p>Company reports positive Phase 2a trial results for ATI-2138 in atopic dermatitis</p></li></ul><p><span>Outlook</span></p><ul><li><p>Aclaris plans Phase 2 trial of ATI-2138 in H1 2026 for new indications</p></li><li><p>Company expects Phase 1b trials of ATI-052 in asthma and AD in H1 2026</p></li><li><p>Aclaris expects cash runway to fund operations into H2 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NET LOSS - Net loss was $14.6 million for the third quarter of 2025 compared to $7.6 million for the third quarter of 2024. </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$3.30 mln</p></td><td><p>$1.59 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$14.61 mln</p></td><td><p>-$15.80 mln (6 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aclaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $7.00, about 67.7% above its November 5 closing price of $2.26</p></li></ul><p>Press Release: <span>ID:nGNX25vlxp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0JM:1","article_id":"2581218062","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581218062","pubTimestamp":1762430862,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aclaris Therapeutics Q3 revenue beats estimates, net loss narrowsOverviewAclaris Q3 revenue beats analyst expectations despite a year-over-year declineNet loss for Q3 smaller than expected, reflecting","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ACRS":"Aclaris Therapeutics"},"translate_title":"Aclaris Therapeutics第三季度收入超出预期，净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRS":0.9},"content_text":"Aclaris Therapeutics Q3 revenue beats estimates, net loss narrowsOverviewAclaris Q3 revenue beats analyst expectations despite a year-over-year declineNet loss for Q3 smaller than expected, reflecting better financial performanceCompany reports positive Phase 2a trial results for ATI-2138 in atopic dermatitisOutlookAclaris plans Phase 2 trial of ATI-2138 in H1 2026 for new indicationsCompany expects Phase 1b trials of ATI-052 in asthma and AD in H1 2026Aclaris expects cash runway to fund operations into H2 2028Result DriversNET LOSS - Net loss was $14.6 million for the third quarter of 2025 compared to $7.6 million for the third quarter of 2024. Key DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueBeat$3.30 mln$1.59 mln (6 Analysts)Q3 Net IncomeBeat-$14.61 mln-$15.80 mln (6 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00, about 67.7% above its November 5 closing price of $2.26Press Release: ID:nGNX25vlxpFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}